89167-24-8

Basic information

• Product Name: 6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE;6-BroMo[1,2,4]triazol[1,5-A]pyriMidine;6-broMo-[1,2,4]triazolo[1,5-a]pyri;[1,2,4]Triazolo[1,5-a]pyrimidine,6-bromo-
• CAS NO: 89167-24-8
• Molecular Formula: C₅H₃BrN₄
• Molecular Weight: 199.02
• Mol File: 89167-24-8.mol

Chemical Properties

• Appearance: /
• Density: 2.13±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(89167-24-8)
• EPA Substance Registry System: 6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(89167-24-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 89167-24-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Chemistry:
6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE is used as a building block for the development of new drugs and bioactive molecules due to its unique structure and reactivity.
Used in Drug Synthesis:
6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE is used as a key intermediate in the synthesis of other organic compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Biological Research:
6-BROMO[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE may exhibit biological activity, making it a valuable tool for researchers to study its potential applications in various biological systems.
Further research and investigation into the properties and potential uses of 6-Bromo[1,2,4]triazolo[1,5-a]pyrimidine are necessary to fully understand its capabilities and applications in different industries.

Upstream product

• 2065-75-0 2-Bromo-malonaldehyde 
• 61-82-5 3-amino-1,2,4-triazole 
• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 21577-50-4 mucobromic acid 
• 61-82-5 4H-1,2,4-triazol-3-amine 

Downstream Products

• 1252803-83-0 6-(3,4-dichlorophenylmethyl)amino-[1,2,4]triazolo[1,5-a]pyrimidine 
• 1421684-99-2 3-([1,2,4]triazolo[1,5-a]pyrimidin-6-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-phenyl)benzamide 
• 1407999-95-4 C₂₈H₂₇F₃N₁₀O 

Relevant articles and documents

ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS

Provided herein are novel compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Microwave-Assisted synthesis and evaluation of antibacterial activity of novel 6-fluoroaryl-[1,2,4]triazolo[1,5-A]pyrimidines

A series of 6-fluoroaryl substituted [1,2,4]triazolo[1,5-A]pyrimidines have been synthesized by using the microwave-Assisted Suzuki cross-coupling reaction from readily available 6-bromo-[1,2,4]triazolo[1,5-A]pyrimidine. The antimicrobial activity of new

A new route for the synthesis of 6-substituted [1,2,4]triazolo[4,3-a] pyrimidines

A new method of generating the fused heterocyclic system with bridgehead nitrogen, triazolo[4,3-a]pyrimidine, from 3-amino-1,2,4-triazole and unsaturated halo acids has been described.

ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS

The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and R4 are as defined herein or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders

Differentiation between [1,2,4]triazolo[1,5-a] pyrimidine and [1,2,4]triazolo[4,3-a]- Pyrimidine regioisomers by 1H-15N HMBC experiments

The condensation of malonoaldehyde derivatives with either a 3-amino-[1,2,4]-triazole or a 3,5-diamino-[1,2,4]-triazole precursor was studied. In agreement with previous reports, two different bicycles, namely, bearing the regioisomeric [1,2,4]triazolo[1,